Valeant 10 21 ownership chart

Valeant Pharmaceuticals (VRX) In Accounting Fraud: Citron

During the rather hostile takeover engineered by Valeant Pharmaceuticals to acquire Allergan, charges were made by Allergan officials that Valeant was “a house of cards,” however no context was provided. A research report from Citron Research today offers context. In a report that is sending Valeant's stock tumbling, Citron claims Valeant is an Enron-like fraud. They offer as proof hidden corporate connections and undocumented demands for what appear as kickback payments from pharmacies that sell drugs to consumers.

exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible


Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers


0